−57KRW
−1.96 BKRW
52.04 BKRW
42.07 M
About MEDIFRON DBT
Sector
Industry
CEO
Sang-Woo Kim
Website
Headquarters
Seoul
Employees (FY)
67
Founded
1997
ISIN
KR7065650004
FIGI
BBG000MSGHT7
Medifron DBT Co., Ltd. engages in the provision of information technology (IT) content services. It operates through the IT and New Medicine business divisions. The IT business division offers interactive voice response system which provides consultation, voicemail, automatic guidance, video conferencing, predictive dialing, audiotext, voice processing function, help desk function, collaborative computing, call switching, and call control. The New Medicine business division develops drugs and diagnostic device for the treatment of central nervous system diseases. The company was founded on March 18, 1997 and is headquartered in Seoul, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 065650 is 1399 KRW — it has increased by 3.63% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange MEDIFRON DBT stocks are traded under the ticker 065650.
MEDIFRON DBT is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
065650 stock is 5.04% volatile and has beta coefficient of 0.82. Check out the list of the most volatile stocks — is MEDIFRON DBT there?
Yes, you can track MEDIFRON DBT financials in yearly and quarterly reports right on TradingView.
065650 stock has risen by 9.98% compared to the previous week, the month change is a 3.12% fall, over the last year MEDIFRON DBT has showed a 10.94% increase.
065650 net income for the last quarter is 8.53 B KRW, while the quarter before that showed 53.91 M KRW of net income which accounts for 15.72 K% change. Track more MEDIFRON DBT financial stats to get the full picture.
Today MEDIFRON DBT has the market capitalization of 84.75 B, it has increased by 1.88% over the last week.
No, 065650 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 065650 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDIFRON DBT stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 67.00 employees. See our rating of the largest employees — is MEDIFRON DBT on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDIFRON DBT technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDIFRON DBT stock shows the sell signal. See more of MEDIFRON DBT technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDIFRON DBT EBITDA is −450.52 M KRW, and current EBITDA margin is −0.87%. See more stats in MEDIFRON DBT financial statements.